SEC filings and other documents

Reduced net loss and strong cash position support ongoing clinical progress into 2028.

KER-065 targets DMD with phase II data in 2027; strong cash runway and pipeline expansion planned.

Net loss of $23.7M in Q1 2026, with strong cash reserves and pipeline progress highlighted.

Elritercept advanced with Takeda, rinvatercept moved into DMD/ALS, and pipeline growth is expected.

Rinvatercept advances in DMD and ALS with strong data and strategic Takeda partnership.

Rinvatercept and elritercept advance in key trials, with strong cash runway into 2028.

2025 net income reached $87M, reversing prior losses, as license revenue offset lower R&D costs.

Net loss narrowed sharply on Takeda license revenue; $375M to be returned to shareholders.

Pipeline refocused on KER-065, with capital return and key clinical milestones ahead.

Q2 2025 featured reduced net loss, major license revenue, and a $375M shareholder return plan.

KER-065 advances in DMD as the company returns $375M to shareholders and streamlines operations.

Pipeline advances in MDS, myelofibrosis, and neuromuscular diseases, with strategic review ongoing.

Takeda license revenue propelled Keros to $148.5M net income and a robust cash position.

Phase I data show KER-065 improves bone, fat, and muscle metrics, supporting phase II in DMD.

Takeda partnership and neuromuscular focus drive pipeline, with key data readouts ahead.

Q2 Tropos data will shape KER-012's future as KER-065 and elritercept advance in key indications.

Pipeline advances, safety-driven pivots, and strong cash reserves shape near-term strategy.

Multiple late-stage assets and a Takeda deal position the pipeline for significant near-term milestones.

$200M Takeda deal boosts cash runway as Keros advances key clinical programs.

Takeda partnership and pipeline advances set up key data milestones in hematology and PAH.

Announced Takeda partnership and advanced PAH and obesity programs with key upcoming data.